Legal & General Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,717
| Closed | -$27.1K | – | 3430 |
|
|
2025
Q2 | $27.1K | Buy |
2,717
+345
| +15% | +$2.78K | ﹤0.01% | 2888 |
|
|
2025
Q1 | $14.2K | Hold |
2,372
| – | – | ﹤0.01% | 3064 |
|
|
2024
Q4 | $18.2K | Sell |
2,372
-14,357
| -86% | -$123K | ﹤0.01% | 3055 |
|
|
2024
Q3 | $171K | Buy |
16,729
+269
| +2% | +$4.1K | ﹤0.01% | 2693 |
|
|
2024
Q2 | $244K | Hold |
16,460
| – | – | ﹤0.01% | 2640 |
|
|
2024
Q1 | $225K | Hold |
16,460
| – | – | ﹤0.01% | 2657 |
|
|
2023
Q4 | $180K | Sell |
16,460
-48,014
| -74% | -$476K | ﹤0.01% | 2715 |
|
|
2023
Q3 | $706K | Buy |
64,474
+582
| +0.9% | +$7.44K | ﹤0.01% | 2308 |
|
|
2023
Q2 | $846K | Buy |
63,892
+5,767
| +10% | +$82.2K | ﹤0.01% | 2283 |
|
|
2023
Q1 | $791K | Sell |
58,125
-940
| -2% | -$16.8K | ﹤0.01% | 2204 |
|
|
2022
Q4 | $1.15M | Buy |
59,065
+1,511
| +3% | +$29.5K | ﹤0.01% | 2112 |
|
|
2022
Q3 | $1.1M | Buy |
57,554
+8,764
| +18% | +$202K | ﹤0.01% | 2116 |
|
|
2022
Q2 | $1M | Buy |
48,790
+3,320
| +7% | +$78.8K | ﹤0.01% | 2156 |
|
|
2022
Q1 | $1.46M | Buy |
45,470
+40,137
| +753% | +$1.46M | ﹤0.01% | 2105 |
|
|
2021
Q4 | $249K | Buy |
5,333
+3,710
| +229% | +$124K | ﹤0.01% | 2624 |
|
|
2021
Q3 | $44K | Hold |
1,623
| – | – | ﹤0.01% | 3014 |
|
|
2021
Q2 | $42K | Sell |
1,623
-1,100
| -40% | -$26.2K | ﹤0.01% | 3004 |
|
|
2021
Q1 | $94K | Buy |
2,723
+1,530
| +128% | +$55.3K | ﹤0.01% | 2639 |
|
|
2020
Q4 | $40K | Hold |
1,193
| – | – | ﹤0.01% | 2863 |
|
|
2020
Q3 | $29K | Buy |
+1,193
| New | +$32.1K | ﹤0.01% | 2857 |
|
Other funds holding ITOS
Legal & General Group's ITOS Position: Q3 2025 in Review
Legal & General Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 2,717 shares — an estimated $27.1K sold.
Legal & General Group first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $1.46M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Legal & General Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Legal & General Group sold 2,717 iTeos Therapeutics shares in Q3 2025, an estimated $27.1K.
- Legal & General Group first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Legal & General Group's iTeos Therapeutics position peaked at $1.46M in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Legal & General Group's 13F filing for Q3 2025, filed 13 Nov 2025.